Hepatitis B Surface Antigen Test · Blood

Hepatitis B can live in your body for years, even decades, without causing a single symptom you would notice. During that time, the virus can slowly scar your liver, raise your risk of liver cancer, and quietly set the stage for organ failure. The only way to know whether you are carrying this virus is a blood test for a protein the virus leaves behind.

That protein is HBsAg (hepatitis B surface antigen), and it is the standard foundation of hepatitis B diagnosis worldwide. If this protein is in your blood, you are infected. If it disappears, your body has achieved what researchers call a functional cure. But HBsAg is more than a yes or no test. Its measured level tells a deeper story about how active the infection is, how likely it is to cause damage, and whether treatment is working.

What HBsAg Actually Is

HBsAg is the outer coat protein of the hepatitis B virus. Infected liver cells produce it in large quantities, releasing it into the bloodstream both as part of complete virus particles and as empty protein shells that outnumber actual virus by a factor of thousands. Because of this overproduction, HBsAg is detectable even when the amount of actual virus in the blood is very low.

The protein comes from two sources inside your liver cells. The first is cccDNA (covalently closed circular DNA), a small, stable ring of viral genetic material that hides inside the cell's command center and acts as a persistent template for new virus. The second is viral DNA that has permanently inserted itself into your own chromosomes. This integrated DNA can keep pumping out HBsAg even when viral replication has been suppressed by medication, which is why HBsAg can remain positive for years on antiviral therapy.

Why Your HBsAg Level Matters

For decades, HBsAg was treated as a simple binary: positive means infected, negative means not. That view is outdated. Modern lab tests can measure exactly how much HBsAg is circulating, reported in international units per milliliter (IU/mL), and those numbers carry real clinical meaning.

In people who test positive for HBeAg (hepatitis B e antigen, a separate viral protein that signals high replication), HBsAg levels tend to be very high, often 10,000 to 100,000 IU/mL. These levels correlate with a large pool of infected liver cells and active viral copying. In people who are HBeAg negative with low viral DNA, the HBsAg level helps separate two very different groups: those at low risk (inactive carriers) and those whose liver disease may be quietly progressing.

Liver Cancer Risk

Chronic hepatitis B is one of the strongest risk factors for liver cancer (hepatocellular carcinoma, or HCC). Among HBeAg-negative carriers with low viral DNA, those with HBsAg at or above 1,000 IU/mL had roughly 14 times the risk of developing liver cancer compared to those below that threshold, after adjusting for other factors. This means that even when the virus appears to be doing very little, the amount of surface antigen circulating in your blood can flag hidden danger.

If you carry hepatitis B and your HBsAg eventually disappears from your blood (a process called seroclearance), your cancer risk drops dramatically. A meta-analysis pooling 28 studies and over 188,000 patients found that people who cleared HBsAg had about 70% lower risk of liver cancer (pooled risk ratio 0.30), about 72% lower risk of liver failure, where the liver loses the ability to keep up with the body's needs (risk ratio 0.28), and about 78% lower risk of needing a liver transplant or dying from liver disease (risk ratio 0.22) compared to those who remained HBsAg positive. All of these reductions held after accounting for other risk factors.

A separate meta-analysis of 28 studies with nearly 35,000 patients confirmed that cancer risk dropped by about two-thirds (risk ratio 0.34) in those who achieved HBsAg seroclearance compared to those with persistent HBsAg. Among non-cirrhotic patients without hepatitis C coinfection, the residual HCC rate after clearance was about 1.55%, meaning the risk is greatly reduced but not zero, particularly if cirrhosis was already present or if clearance happened after age 50.

Total Mortality and Extrahepatic Disease

The consequences of carrying HBsAg extend beyond the liver. A massive prospective study of nearly 476,000 Chinese adults, followed for about a decade with over 35,000 deaths, found that HBsAg-positive individuals had roughly double the overall death rate compared to HBsAg-negative individuals (hazard ratio 2.01). The excess risk was concentrated in liver cancer (about 14 times higher risk) and liver-related infections (about 10 times higher), but also reached into unexpected territory.

The same study found a 38% higher risk of bleeding stroke (intracerebral hemorrhage) and a 31% higher risk of heart disease caused by reduced blood flow to the heart among HBsAg carriers. A follow-up analysis of over 500,000 adults and 59,000 strokes confirmed that HBsAg positivity was linked to a 29% increase in hemorrhagic stroke risk, likely mediated by liver dysfunction affecting blood clotting proteins and the way the body processes fats. These findings were adjusted for demographics, lifestyle, diet, BMI, diabetes, and blood pressure.

Kidney Transplant Outcomes

For anyone undergoing or considering a kidney transplant, HBsAg status matters. A meta-analysis of six observational cohorts covering over 6,000 renal transplant recipients found that HBsAg-positive patients had roughly 2.5 times the risk of dying (risk ratio 2.49) and about 44% higher risk of graft failure (risk ratio 1.44) compared to HBsAg-negative recipients. These pooled estimates came from analyses that adjusted for other transplant-related factors, meaning the excess risk persisted after accounting for confounders.

Reference Ranges and Risk Tiers

HBsAg does not have a normal range the way cholesterol or blood sugar does. Instead, clinicians use specific thresholds to categorize risk. These cutpoints come from large Asian cohort studies (particularly the REVEAL-HBV and ERADICATE-B studies) and international treatment withdrawal cohorts, and they apply primarily to people already known to be HBsAg positive. The following tiers assume HBeAg-negative status and low viral DNA (below 2,000 IU/mL).

These tiers may behave slightly differently across ethnic groups. International data from the RETRACT-B cohort of 1,552 patients suggest that for White patients, the threshold of 1,000 IU/mL gives useful separation, while for Asian patients, 100 IU/mL is a more discriminating cutpoint for predicting outcomes after stopping antiviral medication. Always compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

HBsAg is one of the more stable biomarkers you can test. Unlike inflammatory markers that bounce around with a cold or a hard workout, HBsAg levels change slowly, over months to years, driven by the interplay between your immune system and the virus. Short-term factors like fasting, time of day, recent exercise, or a meal before your blood draw have no documented effect on HBsAg results.

The main scenarios where HBsAg results can mislead involve immune suppression. Drugs like rituximab (used for lymphoma and autoimmune diseases), high-dose steroids, and some chemotherapy regimens can cause a previously suppressed hepatitis B infection to flare back. In someone who had cleared HBsAg years ago, these drugs can make HBsAg reappear in the blood, not as a false positive but as genuine viral reactivation that may require urgent antiviral treatment.

Very low-level HBsAg can sometimes escape detection by standard lab tests. Ultra-sensitive research tests with detection limits 10 to 100 times lower than clinical tests have found HBsAg-positive results in patients classified as negative by routine testing, particularly among people with non-HBV-related liver cancer. For clinical purposes, a standard negative result is reliable, but if you have known risk factors and a negative test, your doctor may want to check additional markers like anti-HBc (hepatitis B core antibody) to rule out past or hidden infection.

Tracking Your Trend

A single HBsAg test tells you whether you are infected. Serial testing tells you where the infection is heading. On long-term antiviral therapy with drugs like entecavir or tenofovir, HBsAg declines at an average rate of about 0.08 to 0.10 log IU/mL per year, which translates to roughly a 20% annual reduction. At that pace, modeling studies estimate it would take a median of about 52 years to reach HBsAg clearance on medication alone, which is why newer treatment strategies are so actively being pursued.

The clinically meaningful change to watch for is a drop of 0.5 to 1.0 log IU/mL (roughly a 70% to 90% decline from your starting point) sustained over months. This kind of decline, especially early in treatment, predicts a much higher chance of eventually losing HBsAg entirely. If your levels are not moving at all after a year of treatment, that information matters too, as it may influence whether your physician adds or switches therapies.

For anyone on antiviral treatment, check quantitative HBsAg at baseline, then every 6 to 12 months to gauge the trajectory. If you are an inactive carrier not on treatment (HBsAg below 1,000 IU/mL with low viral DNA and normal liver enzymes), annual quantitative HBsAg along with ALT and HBV DNA is a reasonable monitoring cadence. If your HBsAg drops below 100 IU/mL, that is a strong signal of favorable immune control and a good time to discuss with your hepatologist whether treatment withdrawal might accelerate clearance.

What to Do With an Abnormal Result

If you test HBsAg positive for the first time, the next step is a full hepatitis B workup: HBV DNA (viral load), HBeAg and anti-HBe (to determine viral phase), liver enzymes (ALT, AST), and a liver fibrosis assessment (either FibroScan, a painless scan that measures liver stiffness, or blood-based scores). These companion tests transform a single HBsAg-positive result into a complete picture of where the infection stands and whether treatment is needed now, soon, or can wait with monitoring.

If your quantitative HBsAg is above 1,000 IU/mL despite low viral DNA, you should be in a hepatocellular carcinoma surveillance program, typically with liver ultrasound and alpha-fetoprotein (AFP) testing every 6 months. A hepatologist or gastroenterologist experienced in viral hepatitis is the right specialist to guide long-term management. If your HBsAg has been tracked over time and is declining steadily toward 100 IU/mL, you and your specialist may want to discuss finite therapy strategies, where stopping antiviral medication under close monitoring can trigger immune clearance of the virus in a meaningful minority of patients.

If you previously tested HBsAg negative but are about to start immunosuppressive therapy (chemotherapy, biologics, high-dose steroids), get retested. Also check anti-HBc, because even a past, resolved infection can reactivate under immune suppression. Knowing your status before starting these medications can prevent a potentially life-threatening hepatitis flare.